Scarica l'app Stockscreener
35.00
5.96%
-2.22
Dopo l'orario di chiusura:
35.00
Precedente Chiudi:
$37.22
Aprire:
$37.27
Volume 24 ore:
2.35M
Relative Volume:
3.69
Capitalizzazione di mercato:
$2.03B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
3.081
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-12.50%
1M Prestazione:
+1.83%
6M Prestazione:
+1.77%
1 anno Prestazione:
-21.35%
Intervallo 1D:
$34.32
$38.43
Intervallo di 1 settimana:
$34.32
$40.80
Portata 52W:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.00 | 2.16B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios (AGIO) Q2 Revenue Jumps 45% - The Globe and Mail
Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN
Why is Agios Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Forecasts From AI Tools - jammulinksnews.com
How strong is Agios Pharmaceuticals Inc. company’s balance sheetPre Market Forecasts For 2025 - jammulinksnews.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript - Insider Monkey
Agios 2025 Q2 Earnings Misses Targets as Net Income Declines 16.5% - AInvest
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlight - GuruFocus
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals: Q2 Earnings Snapshot - Norwalk Hour
Agios Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals: Navigating Earnings Volatility for Long-Term Growth in Rare Disease Therapeutics - AInvest
Earnings call transcript: Agios Pharm Q2 2025 earnings miss EPS, stock dips - Investing.com Canada
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
How many analysts rate Agios Pharmaceuticals Inc. as a “Buy”Top Growth Target Finder To Watch Now - jammulinksnews.com
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports $12.5 Million in Q2 2025 PYRUKYND® Revenues and Highlights Key Regulatory Developments - Quiver Quantitative
Agios Pharmaceuticals: Earnings Beat and Pipeline Offer Glimmers of Hope in Biotech's Volatile Landscape - AInvest
Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com
Intrahepatic Cholangiocarcinoma Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bay - Barchart.com
Live Scanner Shows Breakout on Agios Pharmaceuticals Inc.Technical Stock Breakout Predictions Signal Entry Points - metal.it
When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
What is Agios Pharmaceuticals Inc. company’s growth strategyMassive wealth growth - jammulinksnews.com
What are the latest earnings results for Agios Pharmaceuticals Inc.High-yield capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Invest confidently with data-backed picks - jammulinksnews.com
What drives Agios Pharmaceuticals Inc. stock priceRecord-breaking gains - PrintWeekIndia
What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus
Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus
Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus
Agios Pharmaceuticals price target lowered to $51 from $52 at BofA - TipRanks
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $51 - 富途牛牛
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Jul 10 '25 |
Sale |
40.00 |
1,400 |
56,000 |
17,603 |
| Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Option Exercise |
25.01 |
11,914 |
297,969 |
73,185 |
| Gheuens Sarah | Chief Medical Officer |
Jul 09 '25 |
Sale |
37.99 |
11,914 |
452,601 |
61,271 |
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):